Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Riverwater Partners LLC

Riverwater Partners LLC increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 28.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,368 shares of the medical equipment provider's stock after buying an additional 3,186 shares during the period. Riverwater Partners LLC's holdings in Lantheus were worth $1,402,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D increased its stake in Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider's stock worth $2,364,000 after buying an additional 115 shares during the period. Avantax Advisory Services Inc. increased its position in shares of Lantheus by 5.9% in the 4th quarter. Avantax Advisory Services Inc. now owns 2,382 shares of the medical equipment provider's stock valued at $213,000 after purchasing an additional 132 shares during the last quarter. Foundry Partners LLC increased its position in shares of Lantheus by 4.5% in the 4th quarter. Foundry Partners LLC now owns 3,103 shares of the medical equipment provider's stock valued at $278,000 after purchasing an additional 133 shares during the last quarter. Moody National Bank Trust Division increased its position in shares of Lantheus by 1.0% in the 1st quarter. Moody National Bank Trust Division now owns 14,910 shares of the medical equipment provider's stock valued at $1,455,000 after purchasing an additional 141 shares during the last quarter. Finally, Aurora Investment Counsel increased its position in shares of Lantheus by 0.8% in the 4th quarter. Aurora Investment Counsel now owns 19,200 shares of the medical equipment provider's stock valued at $1,718,000 after purchasing an additional 146 shares during the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the sale, the director now owns 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have commented on LNTH. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. B. Riley cut their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, Truist Financial lowered their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $132.67.

Lantheus Stock Performance

Shares of LNTH stock traded up $0.20 during mid-day trading on Friday, hitting $79.19. 1,537,546 shares of the stock were exchanged, compared to its average volume of 1,018,690. The stock's fifty day simple moving average is $86.79 and its two-hundred day simple moving average is $91.00. The stock has a market capitalization of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.11. Lantheus Holdings, Inc. has a 12-month low of $73.11 and a 12-month high of $126.89. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The business had revenue of $372.76 million for the quarter, compared to analyst estimates of $377.37 million. Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The firm's revenue for the quarter was up .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.69 EPS. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.